American Heart Journal
Volume 156, Issue 3 , Pages 556-563 , September 2008

Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: The Atherosclerosis Risk in Communities (ARIC) Study

  • Robert N. Foley, MB

      Affiliations

    • United States Renal Data System, Minneapolis, MN
    • University of Minnesota, Minneapolis, MN
    • Corresponding Author InformationReprint requests: Robert N. Foley, MB, United States Renal Data System, 914 South 8th Street, Suite S-406, Minneapolis, MN 55404.
    • ,
  • Allan J. Collins, MD, FACP

      Affiliations

    • United States Renal Data System, Minneapolis, MN
    • University of Minnesota, Minneapolis, MN
    • ,
  • Areef Ishani, MD, MS

      Affiliations

    • University of Minnesota, Minneapolis, MN
    • ,
  • Philip A. Kalra, MD

      Affiliations

    • Department of Renal Medicine, Hope Hospital, Salford, UK

Received 11 February 2008 ,Accepted 14 May 2008.

References 

  1. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607–617
  2. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12:2131–2138
  3. Stevens LA, Djurdjev O, Cardew S, et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol. 2004;15:770–779
  4. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005;16:1788–1793
  5. London GM. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol. 2003;14(9 Suppl 4):S305–S309
  6. Porter CJ, Stavroulopoulos A, Roe SD, et al. Detection of coronary and peripheral artery calcification in patients with chronic kidney disease stages 3 and 4, with and without diabetes. Nephrol Dial Transplant. 2007;22:3208–3213
  7. Civilibal M, Caliskan S, Adaletli I, et al. Coronary artery calcifications in children with end-stage renal disease. Pediatr Nephrol. 2006;21:1426–1433
  8. Ammirati AL, Dalboni MA, Cendoroglo M, et al. Coronary artery calcification, systemic inflammation markers and mineral metabolism in a peritoneal dialysis population. Nephron Clin Pract. 2006;104:c33–c40
  9. Tomiyama C, Higa A, Dalboni MA, et al. The impact of traditional and non-traditional risk factors on coronary calcification in pre-dialysis patients. Nephrol Dial Transplant. 2006;21:2464–2471
  10. Coen G, Manni M, Agnoli A, et al. Cardiac calcifications: fetuin-A and other risk factors in hemodialysis patients. ASAIO J. 2006;52:150–156
  11. Splendiani G, Morosetti M, Manni M, et al. Cardiac calcium evaluation in hemodialysis patients with multisection spiral computed tomography. Int J Artif Organs. 2004;27:759–765
  12. Oh J, Wunsch R, Turzer M, et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circul. 2002;106:100–105
  13. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–1483
  14. ARIC: Collaborative Studies Coordinating Center, University of North Carolina at Chapel Hill. Available at http://www.cscc.unc.edu/aricLast accessed April 18, 2008
  15. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol. 1989;129:687–702
  16. National Heart Lung and Blood Institute . In: Atherosclerosis Risk in Communities (ARIC) Study: Operations Manual No. 10. Clinical Chemistry Determinations. 1987;p. 1–76[Bethesda (Md)].
  17. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254
  18. High-resolution B-mode ultrasound scanning methods in the Atherosclerosis Risk in Communities Study (ARIC). The ARIC Study Group. J Neuroimaging. 1991;1:68–73
  19. High-resolution B-mode ultrasound reading methods in the Atherosclerosis Risk in Communities (ARIC) cohort. The ARIC Study Group. J Neuroimaging. 1991;1:168–172
  20. Willett WC, Sampson L, Stampfer MJ, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol. 1985;122:51–65
  21. White AD, Folsom AR, Chambless LE, et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. J Clin Epidemiol. 1996;49:223–233
  22. Eilers P, Marx B. Flexible smoothing with B-splines and penalties. Statistical Science. 1996;11:89–121
  23. Eisen EA, Agalliu I, Thurston SW, et al. Smoothing in occupational cohort studies: an illustration based on penalised splines. Occup Environ Med. 2004;61:854–860
  24. Sitara D, Razzaque MS, Hesse M, et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004;23:421–432
  25. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45–51
  26. Morishita K, Shirai A, Kubota M, et al. The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. J Nutr. 2001;131:3182–3188
  27. Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87:E10–E17
  28. Steitz SA, Speer MY, Curinga G, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res. 2001;89:1147–1154
  29. Wada T, McKee MD, Steitz S, et al. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ Res. 1999;84:166–178
  30. Chen NX, O'Neill KD, Duan D, et al. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int. 2002;62:1724–1731
  31. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78–81
  32. Portale AA, Halloran BP, Morris RC. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest. 1989;83:1494–1499
  33. Zittermann A, Schleithoff SS, Tenderich G, et al. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure?. J Am Coll Cardiol. 2003;41:105–112
  34. Smogorzewski M, Zayed M, Zhang YB, et al. Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Am J Physiol. 1993;264(6 Pt 2):H1998–H2006
  35. Amann K, Tornig J, Kugel B, et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int. 2003;63:1296–1301
  36. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245–252
  37. Asmus HG, Braun J, Krause R, et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant. 2005;20:1653–1661
  38. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815–1824
  39. Suki WN, Zabaneh R, Cangiano JL. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;
  40. Tonelli M, Sacks F, Pfeffer M, et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circul. 2005;112:2627–2633
  41. Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007;167:879–885
  42. Qunibi WY. Reducing the burden of cardiovascular calcification in patients with chronic kidney disease. J Am Soc Nephrol. 2005;16(Suppl 2):S95–S102

 This study was supported by the United States Renal Data System under contract no. HHSN267200715002C (National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD). Doctor Foley has received honoraria from Genzyme (Cambridge, MA) and Abbott (Abbott Park, IL). Doctor Collins has received consulting fees from Roche (Basel, Switzerland) and Amgen (Thousand Oaks, CA). Doctor Kalra has received educational grants from Amgen and Genzyme. Doctor Ishani has no conflicts of interest.

PII: S0002-8703(08)00388-8

doi: 10.1016/j.ahj.2008.05.016

American Heart Journal
Volume 156, Issue 3 , Pages 556-563 , September 2008

Article Tools

* Image Usage & Resolution